- Conditions
- Triple Negative Breast Cancer
- Interventions
- Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 188
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more
Location Directory
Clinical trials in Baltimore, Maryland
This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
13749
Shown on this page
12
Current sort
Recently updated
Location scope
Baltimore, MD
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 433–444 of 13,749 matching trials in Baltimore, MD.
Live ClinicalTrials.gov results.
Institutions in Baltimore
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Autism Spectrum Disorder, Anxiety Disorders
- Interventions
- DINOSAUR, Psychoeducation
- Behavioral · Other
- Lead sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Other
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 67
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Seltorexant, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 39
- States / cities
- Bryant, Arkansas • Bellflower, California • Glendale, California + 31 more
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
- Interventions
- ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
- Device · Drug
- Lead sponsor
- Inari Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
- Conditions
- DLBCL, Diffuse Large B-Cell Lymphoma
- Interventions
- Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine, Granulocyte Colony-Stimulating Factor (G-CSF)
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 26
- States / cities
- Glendale, Arizona • Beverly Hills, California • Walnut Creek, California + 23 more
- Conditions
- Healthy Eating Index
- Interventions
- Multilevel restaurant intervention to improve the food environment
- Behavioral
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 756 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Colorectal Neoplasms
- Interventions
- Amivantamab, Cetuximab, Bevacizumab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Irinotecan
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 71
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Prescott, Arizona + 60 more
- Conditions
- Central Centrifugal Cicatricial Alopecia (CCCA)
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbia, Maryland
- Conditions
- Cushing Syndrome
- Interventions
- relacorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Stanford, California • Torrance, California + 21 more
- Conditions
- Multiple Myeloma
- Interventions
- Talquetamab, Daratumumab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Norwalk, Connecticut + 30 more
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- sorafenib tosylate, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 16 more